The Potential of Flavonoids in the Treatment of Non-alcoholic Fatty Liver Disease

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The contemporary pathophysiological model of non-alcoholic fatty liver disease (NAFLD) consists of multiple parallel pathways with a dynamic cross talk that cumulate in steatosis and inflammation and ultimately fibrosis, cirrhosis, liver failure and hepatocellular carcinoma. So far, no pharmacological treatment has been approved. A major impediment of drugs in general is that they are intended to act on one single target in the pathology of a disease. However, the multitude of pathways involved in the pathogenesis of NAFLD underpins the need for treatments that address these various pathways. Interestingly, flavonoids have been found to have positive effects on lipid metabolism, insulin resistance, inflammation and oxidative stress, the most important pathophysiological pathways in NAFLD. This puts flavonoids in the spotlight for the treatment of NAFLD and prompted us to review the existing evidence for the use of these food derived compounds in the treatment of NAFLD.
Original languageEnglish
Pages (from-to)834-855
Number of pages22
JournalCritical Reviews in Food Science and Nutrition
Volume57
Issue number4
DOIs
Publication statusPublished - 2017

Keywords

  • NAFLD
  • non-alcoholic steatohepatitis
  • polyphenols
  • oxidative stress
  • antioxidants
  • GREEN TEA EXTRACT
  • NF-KAPPA-B
  • DIET-INDUCED OBESITY
  • HEME OXYGENASE 1
  • HEPATIC STEATOSIS
  • OXIDATIVE STRESS
  • METABOLIC SYNDROME
  • RAT MODEL
  • INSULIN-RESISTANCE
  • LIPID-ACCUMULATION

Cite this

@article{927ba8a8ddd84cfcadad02a56115ee80,
title = "The Potential of Flavonoids in the Treatment of Non-alcoholic Fatty Liver Disease",
abstract = "The contemporary pathophysiological model of non-alcoholic fatty liver disease (NAFLD) consists of multiple parallel pathways with a dynamic cross talk that cumulate in steatosis and inflammation and ultimately fibrosis, cirrhosis, liver failure and hepatocellular carcinoma. So far, no pharmacological treatment has been approved. A major impediment of drugs in general is that they are intended to act on one single target in the pathology of a disease. However, the multitude of pathways involved in the pathogenesis of NAFLD underpins the need for treatments that address these various pathways. Interestingly, flavonoids have been found to have positive effects on lipid metabolism, insulin resistance, inflammation and oxidative stress, the most important pathophysiological pathways in NAFLD. This puts flavonoids in the spotlight for the treatment of NAFLD and prompted us to review the existing evidence for the use of these food derived compounds in the treatment of NAFLD.",
keywords = "NAFLD, non-alcoholic steatohepatitis, polyphenols, oxidative stress, antioxidants, GREEN TEA EXTRACT, NF-KAPPA-B, DIET-INDUCED OBESITY, HEME OXYGENASE 1, HEPATIC STEATOSIS, OXIDATIVE STRESS, METABOLIC SYNDROME, RAT MODEL, INSULIN-RESISTANCE, LIPID-ACCUMULATION",
author = "{van de Wier}, B. and Koek, {Ger H.} and A. Bast and Haenen, {Guido R.M.}",
year = "2017",
doi = "10.1080/10408398.2014.952399",
language = "English",
volume = "57",
pages = "834--855",
journal = "Critical Reviews in Food Science and Nutrition",
issn = "1040-8398",
publisher = "Routledge/Taylor & Francis Group",
number = "4",

}

The Potential of Flavonoids in the Treatment of Non-alcoholic Fatty Liver Disease. / van de Wier, B.; Koek, Ger H.; Bast, A.; Haenen, Guido R.M.

In: Critical Reviews in Food Science and Nutrition, Vol. 57, No. 4, 2017, p. 834-855.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - The Potential of Flavonoids in the Treatment of Non-alcoholic Fatty Liver Disease

AU - van de Wier, B.

AU - Koek, Ger H.

AU - Bast, A.

AU - Haenen, Guido R.M.

PY - 2017

Y1 - 2017

N2 - The contemporary pathophysiological model of non-alcoholic fatty liver disease (NAFLD) consists of multiple parallel pathways with a dynamic cross talk that cumulate in steatosis and inflammation and ultimately fibrosis, cirrhosis, liver failure and hepatocellular carcinoma. So far, no pharmacological treatment has been approved. A major impediment of drugs in general is that they are intended to act on one single target in the pathology of a disease. However, the multitude of pathways involved in the pathogenesis of NAFLD underpins the need for treatments that address these various pathways. Interestingly, flavonoids have been found to have positive effects on lipid metabolism, insulin resistance, inflammation and oxidative stress, the most important pathophysiological pathways in NAFLD. This puts flavonoids in the spotlight for the treatment of NAFLD and prompted us to review the existing evidence for the use of these food derived compounds in the treatment of NAFLD.

AB - The contemporary pathophysiological model of non-alcoholic fatty liver disease (NAFLD) consists of multiple parallel pathways with a dynamic cross talk that cumulate in steatosis and inflammation and ultimately fibrosis, cirrhosis, liver failure and hepatocellular carcinoma. So far, no pharmacological treatment has been approved. A major impediment of drugs in general is that they are intended to act on one single target in the pathology of a disease. However, the multitude of pathways involved in the pathogenesis of NAFLD underpins the need for treatments that address these various pathways. Interestingly, flavonoids have been found to have positive effects on lipid metabolism, insulin resistance, inflammation and oxidative stress, the most important pathophysiological pathways in NAFLD. This puts flavonoids in the spotlight for the treatment of NAFLD and prompted us to review the existing evidence for the use of these food derived compounds in the treatment of NAFLD.

KW - NAFLD

KW - non-alcoholic steatohepatitis

KW - polyphenols

KW - oxidative stress

KW - antioxidants

KW - GREEN TEA EXTRACT

KW - NF-KAPPA-B

KW - DIET-INDUCED OBESITY

KW - HEME OXYGENASE 1

KW - HEPATIC STEATOSIS

KW - OXIDATIVE STRESS

KW - METABOLIC SYNDROME

KW - RAT MODEL

KW - INSULIN-RESISTANCE

KW - LIPID-ACCUMULATION

U2 - 10.1080/10408398.2014.952399

DO - 10.1080/10408398.2014.952399

M3 - Article

VL - 57

SP - 834

EP - 855

JO - Critical Reviews in Food Science and Nutrition

JF - Critical Reviews in Food Science and Nutrition

SN - 1040-8398

IS - 4

ER -